Drug Profile
Celecoxib - Promius Pharma
Alternative Names: DFN-15; DFN-15A; DFN-15B; ELYXYBLatest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator Promius Pharma
- Developer BioDelivery Sciences International; Scilex Holding
- Class Antimigraines; Antineoplastics; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules; Sulfonamides
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Migraine
- Phase II Postoperative pain
Most Recent Events
- 19 Mar 2024 Scilex Holding responded to questions on the product composition in the ELYXYB patent from Health Canada’s Office of Patented Medicines and Liaison (OPML) during review of a New Drug Submission to Health Canada’s Pharmaceutical Drugs Directorate for migraine in Canada
- 08 Jan 2024 Scilex Holding expect approval for Celecoxib for Postoperative pain in USA in 2024
- 26 Dec 2023 Preregistration for Migraine in Canada (PO)